Anticoagulation in hospitalized patients with COVID-19.
Lisa Baumann KreuzigerMichelle SholzbergAndrea N EdgintonPublished in: Blood (2022)
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
Keyphrases
- venous thromboembolism
- coronavirus disease
- direct oral anticoagulants
- healthcare
- sars cov
- magnetic resonance
- respiratory syndrome coronavirus
- palliative care
- risk factors
- pulmonary embolism
- clinical practice
- atrial fibrillation
- growth factor
- clinical trial
- quality improvement
- case report
- chronic pain
- affordable care act